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Abstract 
 Betaine homocysteine methyltransferase (BHMT), a Zn2+-dependent thiolmethyltransferase, 
contributes to the regulation of homocysteine levels, whose increases are considered a risk factor 
for cardiovascular diseases. Most plasma homocysteine is generated through the liver methionine 
cycle, in which BHMT metabolizes approximately 25% of this non-protein amino acid. This 
process allows recovery of one of the three methylation equivalents used in phosphatidylcholine 
synthesis through transmethylation, a major homocysteine producing pathway. Although BHMT 
has been known for over 40 years the difficulties encountered in its isolation precluded detailed 
studies until very recently. Thus, the last 10 years, since the sequence became available, have 
yielded extensive structural and functional data. Moreover, recent findings offer clues for potential 
new functions for BHMT. The purpose of this review is to provide an integrated view of the 
knowledge available on BHMT, and to analyze its putative roles in other processes through 
interactions undercover to date.  
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Abbreviations. 
 Hcy, homocysteine; tHcy, plasma total homocysteine; SAH, S-adenosylhomocysteine; 
SAHH, S-adenosylhomocysteine hydrolase; MS, methionine synthase; BHMT, betaine 
homocysteine methyltransferase; CBS, cystathionine ? synthase; SAM, S-adenosylmethionine; 
MTHF, methyl tetrahydrofolate; PC, phosphatidylcholine; CB-Hcy, S-(?-carboxylbutyl)-L-Hcy; 
DMG, dimethylglycine; MMTS, methylmethane thiosulfonate; MAD, multiple anomalous 
diffraction; DA, dimerization arm; MTHFR, methylenetetrahydrofolate reductase; CT?, CTP-
phosphocholine cytidylyltransferase; PEMT, phospholipid methyltransferase; PrP, prion protein; 
DIGE, difference gel electrophoresis; HCV, hepatitis C virus; HBV, hepatitis B virus.  
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In recent years homocysteine [Hcy] has become a subject of great interest, due to its implication 
as a risk factor for cardiovascular diseases. However, increases in its plasma levels [tHcy] have also 
been detected in disorders such as psoriasis, renal insufficiency, spina bifida, Alzheimer, cognitive 
impairment in the elderly and adverse pregnancy outcome [1-4]. Elevated levels of tHcy are very 
common, in fact, they can be detected in 10-20% of the normal population as a result of genetic [4] 
and nongenetic factors [3,5]. The present interest in Hcy metabolism has brought to the front page 
the knowledge accumulated for over 50 years in this branch point of the methionine cycle and its 
relationships to a number of key cellular processes (Figure 1) [6]. Most of the available information 
has been obtained in liver, which processes 48% of the ingested methionine in humans [6]. Hence, 
the role of liver as the main regulator of tHcy levels has been suggested [7]. Hcy a non-protein thiol 
amino acid is generated through a reaction catalyzed by S-adenosylhomocysteine hydrolase 
[SAHH] that breaks the S-adenosylhomocysteine [SAH] produced through S-adenosylmethionine 
[SAM] dependent methylations in Hcy and adenosine. This reaction is reversible and 
thermodynamically favors the synthesis of SAH, a potent inhibitor for many methylation reactions. 
In order to keep the levels of this inhibitor under control, elimination of the reaction products has to 
be coordinated with their synthesis. Thus, adenosine is metabolized by adenosine deaminase, whose 
Km in the low micromolar range favors elimination under all conditions, whereas Hcy can be 
metabolized through several routes that differ in their Km values, hence favoring one or another 
according to the cell needs (Figure 1): 1) synthesis of cystathionine, and thus entrance to the trans-
sulfuration pathway; 2) methylation to methionine, which can take place through the action of either 
methionine synthase [MS] or betaine homocysteine methyltransferase [BHMT]; and 3) export to the 
plasma. The trans-sulfuration pathway includes two reactions that depend on pyridoxal phosphate, 
those catalyzed by cystathionine ? synthase [CBS] and cystathionase or cysthathionine ? lyase 
[C?L] that lead to the synthesis of cystathionine and cysteine, respectively (Figure 1) [6]. These 
reactions yield cysteine for protein and glutathione synthesis, provided a sufficient intake of 
methionine to the mammalian cell. On the other hand, the methylation reactions involved in 
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methionine synthesis link Hcy with the folate cycle and phosphatidylcholine [PC] metabolism. 
These are two of the few methylation reactions known to use methyl donors other than SAM. MS 
uses methyl tetrahydrofolate [MTHF] in a reaction that needs cobalamine in mammals, whereas 
BHMT utilizes betaine. In spite of the broad knowledge on the methionine cycle, the difficulties 
encountered in the purification of BHMT have long precluded a thorough investigation of this 
enzyme until 1996 when Garrow cloned the human protein [8]. Ever since a large amount of 
structural and functional data about various mammalian BHMTs has emerged which makes a 
revision pertinent attempting to integrate this knowledge in order to offer a general view of the 
current status of this field. 
1. Betaine homocysteine S-methyltransferase general aspects.  
BHMT catalyzes resynthesis of methionine using Hcy and the methyl donor betaine. It has 
been calculated that this reaction processes 25% of the cellular Hcy in an in vitro model of rat liver 
[9], also allowing recovery of part of the methylation equivalents (through betaine) used in PC 
synthesis, as explained below. This last point acquires more relevance because phospholipid 
methyltransferase [PEMT] and guanidinoacetate methyltransferase are responsible for most of the 
cellular Hcy production (Figure 1)[4]. Moreover, BHMT is also involved in regulation of tonicity in 
liver and kidney [10], since betaine exerts an important role as a cellular osmolyte to maintain 
cellular volume [11], and in the prevention of protein unfolding. Betaine is obtained from the diet, 
large amounts of this compound being found in seafood, wheat germ or bran and spinach [10], 
whereas in mammalian cells it can be produced through choline oxidation that is mainly carried out 
in liver and kidney (Figure 1)[12]. This process occurs in the mitochondria and is catalyzed in two 
consecutive reactions by choline oxidase and betaine aldehyde dehydrogenase [13]. Choline is 
obtained either from the diet or from PC, one of the main phospholipids of membranes that can be 
synthesized by the Kennedy [14] and transmethylation pathways [15], the first of them being the 
most important in every cell type. On the other hand, transmethylation acquires more importance in 
the hepatocyte, where it can render about 40% of the PC synthesized by this cell [16]. In this 
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process, phosphatidylethanolamine has to be methylated in three consecutive reactions using SAM 
as the methyl donor. PC degradation through phospholipase D renders phosphatidic acid and 
choline that enters the mitochondrial matrix from the cytosol using a specific transporter [17], 
whereas upon oxidation betaine is extruded back to the cytosol by simple diffusion [13]. Thus, the 
overall result is that synthesis of choline by methylation consumes three SAM molecules and 
methylation of Hcy by BHMT allows the recovery of one of these methylation equivalents to the 
methionine cycle, whereas the remaining four carbons of choline enter the one-carbon pool.  
2. The BHMT gene.  
The BHMT gene contains 8 exons and 7 introns [18,19] and in human locates to 
chromosome 5q13.1-5q15 [20]. BlastN search showed a 61% identity between human and mouse 
genes. 5’-RACE of human liver or HepG2 cells mRNA indicates a single species, whose ORF 
codifies for a 406 amino acid protein. Analysis of the 5’-end of genomic DNA revealed a possible 
TATA box 26 bp and 28 bp upstream the transcription initiation site for the human and mouse 
genes, respectively [18,19]. In addition, 5’ of the human TATA box putative sites for several 
transcription factors are located, including Sp1 (4), activator protein 2 (1), liver-specific or liver-
enriched factors HNF-1, HNF-3 and CAAT enhancer binding protein, homeobox 4c, 4d and 4e and 
steroid receptors (glucocorticoids, progesterone, estrogens and androgens). This area of the mouse 
gene contains putative Sp1, AP2, AP4, NF1, GATA and CCAAT sites. In the 3’ of the TATA box, 
two more Sp1 sites have been identified in the human gene. Analysis of human promoter activity 
was performed in HepG2 cells [21], where only constructions including the TATA box showed 
transcriptional activity, the region –254/+1 containing all the essential elements for basal activity. 
Some negative regulatory elements are located in the region comprising –1793/-1063 with 
compensatory elements at –3175/-1793. Addition of methionine or ethionine to the HepG2 medium 
had no effect, whereas SAM reduced the activity. SAM responsive elements have been located at –
254/+1 [21]. However, to date, experimental data have only identified putative sites of regulation, 
and hence efforts to study the role of these regulatory elements in depth should be considered, 
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especially in the light of the hormonal effects described in early studies and that are mentioned 
below. 
In addition to these observations, screening of a mouse genomic library and a yeast two 
hybrid study allowed identification of a BHMT pseudogene (mBHMTps)[19] and a transcript with 
80% identity to BHMT called BHMT2 [2], respectively. The sequence of the pseudogene showed 
97% homology to mouse BHMT and contains a 1190 bp ORF [19]. The BHMT2 gene is located at 
chromosome 5q13.1-5q13.2, its ORF codifies for a protein of 363 amino acids, approximately 40.3 
kDa and pI 5.61, and its origin seems a tandem duplication phenomenon [2]. At present, there is no 
information regarding the role of these new forms of BHMT. However, BHMT2 lacks 
approximately 40 residues of the C-terminal, a fact that on the light of the BHMT structural and 
folding data available may be crucial for its stability. 
3. Betaine homocysteine S-methyltransferase distribution.  
BHMT has been detected in eukaryotes and prokaryotes [22-24]. Most of the studies carried 
out to date have been done in mammals, where the protein can be detected after day 10 of gestation 
[25] and in adults [22]. Activity and expression measurements revealed the liver and kidney as the 
main organs for BHMT and BHMT2 location [2,8,22,26]. BHMT is very abundant in the liver in 
most species, representing 0.6-1.6% of the total protein [8,22,26], whereas in the kidney the activity 
observed is lower for human and pig, and very low for rats [22,27]. In contrast, in sheep, the highest 
levels of activity correspond to the pancreas [28], such a distribution being attributed to the low 
oxidation of choline observed in these animals that could be an adaptation mechanism to the 
reduced levels of this metabolite in ruminant diets. BHMT has also been detected in lens of Rhesus 
monkey (Macaca mulatta), where it represents 0.5-10% of the total protein [29]. In this structure 
BHMT appears concentrated in the oldest cells of the lens nucleus, which lack organelles such as 
nucleus and mitochondria, as well as protein synthesis. Among cell lines BHMT activity has been 
described in hepatoma cells [30], but not in skin fibroblasts or peripheral blood lymphocytes [31].  
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 Subcellular fractionation of rat liver demonstrated BHMT activity only in the cytosol [22]. 
Immunohistochemistry confirmed these results, but also indicated that distribution in human and 
pig liver is homogeneous through the lobule, whereas a gradient with high periportal expression is 
observed in rat [32]. Western blot of human and pig kidney samples showed strong signals in the 
cortex [20], and immunohistochemistry revealed concentrated expression in the cytosol of the 
proximal tubules, in addition to a slight staining in distal tubules and collecting ducts [32]. 
Recently, analyses by SDS-PAGE, mass spectrometry, and immunoblotting of liver membranes 
from C57BL/6J mice have detected BHMT in canalicular membranes and a low signal in 
basolateral membranes [33]. In summary, the fact that the liver and kidney are the main locations 
for BHMTs expression confirms their importance for methionine metabolism and regulation of 
osmotic stress, processes both carried out mainly in these tissues. Moreover, the presence of the 
enzyme in renal cortex, the place of betaine production, rather than in medulla, where its role as 
osmolyte is exerted, speaks in favor of BHMT as a control point for betaine levels. In addition, the 
subcellular distribution of the enzyme is also in agreement with that of the rest of the enzymes 
involved in methionine metabolism, but its presence in hepatocyte membranes and in the lens opens 
the possibility of new roles for this protein. 
4. Enzyme characterization and reaction mechanism.  
Attempts to purify BHMT were carried out using rat, pig and human liver samples 
[8,30,34,35]. SDS-PAGE and gel filtration chromatographies of partially purified preparations 
indicated calculated molecular weights of 45 and 270 kDa, respectively, thus leading to propose 
BHMT as a hexamer of identical subunits. However, crystallization data and sedimentation velocity 
experiments demonstrated later that a tetramer is the association arrangement that better defines 
recombinant BHMT [36-38]. These discrepancies between proteins of animal and recombinant 
origin cannot exclude other arrangements such as those observed in morpheeins that may be 
preferred i.e. after post-translational modifications of the polypeptide chain.  
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 BHMT uses L-Hcy and betaine for the synthesis of methionine and dimethylglycine [DMG] 
following an ordered Bi-Bi mechanism [34,39]. Hcy is the first substrate to be bound and DMG the 
first product to leave, whereas no binding of betaine or DMG is observed in the absence of Hcy. 
Kinetic characterization of the enzyme rendered Km values for betaine and L-Hcy in the micromolar 
range. The values for betaine were calculated to be 100 µM for the human protein, but the latest 
report elevates this value to 2.4 mM [8,30,35]. L-Hcy Km values have been also determined, being 
120 µM for the human liver BHMT, but the non-quantitative hydrolysis procedure used to obtain 
Hcy from Hcy thiolactone make these data variable between assays. Recombinant BHMTs showed 
slight differences in the affinity for the substrates as compared to the animal protein data [40,41]. 
D-Hcy is not a substrate, whereas dimethylacetothetin can substitute for betaine as the methyl donor 
and in this case an increase of 47-fold in Vmax has been observed [8]. The search for inhibitors of the 
enzyme included many metabolites, reducing agents and analogues of the substrates [30,34,35,42-
46]. The potency and effect of all these compounds were tested with proteins of different origins 
and in some cases differences in behavior among BHMTs were observed (table 1). 
5. BHMT structure.  
Mammalian BHMT proteins are highly conserved, in fact human and pig enzymes are 88% 
identical at the nucleotide level and 94% at the amino acid level [8]. BlastP revealed homology to 
regions involved in SAM binding for B12-dependent MS. The motif G[ILV]NCX(20,100)[ALV] 
X(2)-[LV]GGCCX(3)PX(2)I, typical for the structural family of Zn2+-dependent thiol and selenol 
methyltransferases, was also identified. This motif contains three cysteines (217, 299 and 300) 
essential for catalysis as they bind Zn2+ to activate Hcy. This process led to thiolate formation and 
liberation of a proton for nucleophilic attack to the methyl group of betaine [40]. Mutants in these 
cysteines showed no activity and a low Zn2+ content, thus confirming their role in cation binding 
[48]. The fourth ligand for Zn2+ binding was identified as Y160 [49]. Moreover, double mutants at 
positions 214/215 and 297/298 showed very low activity, highlighting their relevance [50]. This 
same study showed that none or only small changes are allowed at these positions, as well as at 301. 
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Moreover, the need for glycines in locations contiguous to the cation binding cysteines giving 
flexibility to this environment was also stated. 
 Crystal structures for the human and rat liver proteins have been obtained [38,49]. The 
human protein used was a mutant in 6 residues (5 non active site cysteines and a proline) and its 
free and Zn2+-ligated structures, as well as its complex with CB-Hcy, were solved by MAD. The 
oxidized form of the protein showed a disulfide bond linking C217 and C299 [38]. The main feature 
of the subunit is a (?/?)8 barrel composed by residues 11-318 of the sequence (Figure 2). Several 
unordered areas are detected in the absence of the cation, while its presence allowed solution of the 
38-52 loop. Residues downstream of 318 form an extended structure called the dimerization arm 
[DA] that interacts with L7 of the opposite monomer. Moreover, a loop comprising residues 362-
365 (the hook) in this DA wraps the equivalent loop of the other monomer. Superposition of the 
hooks provides a flat surface that allows interaction with another dimer generating a tetramer of 
222-point symmetry. Therefore, the BHMT structure obtained is a dimer of dimers with a small 
tetramerization interphase (780 Å2 are buried) [38]. Electron density maps of the transition state 
complex revealed the features and the residues involved in L-Hcy (Zn2+, D26 and E159) and betaine 
(W44, F76, Y77, Y160, F261 and F267) binding [38]. A parallel mutagenesis study carried out on 
the rat BHMT, was in good agreement with the role proposed for these residues in the human 
enzyme [41]. Changes at positions E159 and Y77 showed the largest decreases in activity, but D26 
and F74 seem to have a role in betaine binding, whereas E21 and C186 also influence L-Hcy 
binding [41]. Solution of the rat BHMT crystal showed an ?-helix formed by residues 381-407 
extending from one monomer to the opposite to bind the dimers contributing additional interactions 
to tetramer stabilization [49]. Electronic maps contributed new data such as the N-terminal (1-9) 
and the L2 loop (82-90). This last loop shows high mobility and plays a role in Hcy binding. The 
presence of CB-Hcy provides protection against trypsin proteolysis at loop L2, as well as against 
oxidation [51]. No effect on oligomerization is exerted by the oxidant methylmethane thiosulfonate 
[MMTS], but reversible effects on activity and cation binding were observed. These results and the 
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fact that mutations of non-active site cysteines did not abolish the inhibitory effects of MMTS 
indicate that oxidation occurs on active site cysteines.  
 Mutations at other positions relevant for the rest of the Pfam 02574 family of Zn2+-
dependent thiol and selenol methyltransferases have also been studied [52]. These include stop 
codons at positions equivalent to the last residue in other members of the family and in BHMT2, 
deletions of the C-terminal helix and at the DA. These mutants showed either very low activity and 
expression or could not be purified. Moreover, since BHMT is the only oligomer of the family, 
analysis of the residues at the DA was also carried out. Several mutants, R346A, W352A and 
Y363A, showed alterations in the association state. Elimination of the DA destabilized BHMT 
leading to its rapid degradation in E. coli. Some of the DA residues may also be involved in 
catalysis or substrate binding, as is the case for H338. Structural information about BHMT2 is 
limited to hydrophobic plots of its sequence. Such plots show no evidence of transmembrane 
segments, and thus exclude BHMT2 as an integral membrane protein. Using human and mouse 
sequences Prosite identified sites for putative post-translational modifications [2]. The sequence 
GGCCGTXPXHI of the zinc-binding domain is conserved, but no significant methylation activity 
was observed in the initial report by Chadwick et al.. Future advances in BHMT2 structure may 
shed light on the association level of this protein, as well as on its structure and the differences with 
BHMT.  
6. Insights into BHMT folding.  
Barrels of the (?/?)8 type are the most common fold among the proteins of known structure. 
In fact, it has been calculated that a 10% of the protein structures belong to this group. Most of the 
members of this family whose folding has been studied to date are monomers. Thus, the study of 
oligomers should provide additional knowledge about the contribution of association features to 
stability. Among these oligomers BHMT offers special interest due to the presence of the C-
terminal helix as an extension that keeps the tetramer tighly packed. To date, only equilibrium 
unfolding data for recombinant rat BHMT have been published [53]. However, the high level of 
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identity shown by mammalian BHMTs makes these results extrapolable. Urea has been used as the 
perturbing agent and its effects monitored by several techniques that showed a number of 
transitions. Sedimentation velocity allowed detection of only tetramers and monomers during the 
unfolding process. Analysis of the results indicated a four-step mechanism involving two 
intermediates, a tetramer and a monomer, described as N4-I4-4J-4U. 
 To get a deeper insight into the changes taking place during urea unfolding tryptophan 
mutants were prepared and analyzed by activity measurements and tryptophan fluorescence [53]. 
Only W352F showed a different behavior that corresponds to a low activity dimer, as previously 
described for the analogous human mutant [39,52]. Differences in fluorescence parameters among 
equivalent mutants for recombinant human and rat enzymes exist and have already been discussed 
by Garrido et al. on the light of their relative positions to a number of non-conserved residues 
around them [38,49,53,54]. Unfolding profiles indicate that changes around W331 allow for 
differentiation between dissociation and intermediate denaturation. Comparison of the results for 
wild type and mutants allowed identification of the structures modified as urea concentration 
increases (Figure 2). First, changes around helix ?4 of the barrel (W169) and DA (W331) take 
place before detection of I4. Dissociation of I4 to intermediate J occurs through alterations in the 
loop that connects the C-terminal helix (W373), in the ?7 helix (W279) and the final modifications 
in helix ?4 of the barrel (W169) and DA (W331). Unfolding of intermediate J involves the 
remaining changes in the ?7 helix of the barrel (W279) and in the loop that connects the C-terminal 
helix (W373), as well as the last modifications in secondary structure. These results cannot exclude 
the presence of dimeric intermediates in this process, since as judged from W352F data, those 
would be highly susceptible to urea, and hence difficult to detect. Comparison of BHMT unfolding 
data to those of other (?/?)8 barrels indicate the importance of the additional elements of difference 
(DA and C-terminal helix) to the stability of the subunit and the oligomer.  
7. BHMT regulation.  
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7.1. Dietary effects. Ever since its discovery important efforts have been made to elucidate 
the effects of different dietary compositions on BHMT, the preferred model being the rat. The 
number of studies combining alterations in the dietary content of sulfur amino acids and lipotropes 
is wide, and not always have yielded consistent results. Increases in BHMT activity, protein and 
mRNA levels have been reported with supplements of methionine, choline, betaine or cistine, but 
some of these effects are only obtained when combined with restrictions in another of these 
components [18,55-59]. Feed restriction also increases BHMT activity with small elevations in 
expression, this last effect being ascribed to increased blood glucocorticoids [18]. On the other 
hand, decreases in BHMT activity have been observed with selenium deficient diets, these 
reductions being more pronounced when combining selenium and folate deficiencies [60,61]. Most 
of these dietary conditions also affect related enzymes such as choline oxidase, thus leading to 
alterations in betaine levels or changes in the thiol redox status of the cell inducing oxidative 
processes. Thus, BHMT activity can be modified by the levels of its methyl donor or by oxidation 
of its active site. Other interesting models for studying dietary supplements are sheep and pigs. 
Ruminants fed wheaten diets exhibit elevations of hepatic BHMT activity that are not due to 
methionine deficiency since supplementation with this amino acid produce additional increases, 
while reducing MAT activity and thus, leading to plasmatic hypermethioninemia [62]. Pigs show 
low choline oxidase activity as occurs in humans, and deficiencies in methionine do not affect 
hepatic BHMT, but increase its activity in the kidney. Elevations in the liver activity were detected 
with addition of choline and betaine, whereas choline has no effect in the renal enzyme [63]. 
 The high incidence of alcoholic cirrhosis in developed countries has elicited a deep interest 
in the study of ethanol effects. Those have been explored in combination with different types of 
diets due to its influence in the intestinal absorption of methionine and folic acid [64,65]. Increases 
in hepatic BHMT activity were detected in rats fed diets including 3.5% casein or liquid diets 
including ethanol [65,66] and further elevations were observed by addition of betaine to the liquid 
diets [67]. Micropigs fed folate deficient diets showed increased BHMT activity, which was 
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partially blocked by ethanol [68]. In other animal models, such as Syrian hamsters, increases in 
BHMT activity induced by ethanol were only observed when 4-methylpyrazole, an inhibitor of 
alcohol dehydrogenase, was included in the treatment [69]. Altogether these results indicate an 
interplay between ethanol and not only the diet composition, but also its presentation. Moreover, the 
effects of alcohol will also depend on the animal model of choice, especially if its ADH levels are 
high. 
 7.2. Hormonal treatments. As described before, BHMT promoter contains regulatory 
elements for several hormones and future studies will take advantage of this knowledge. However, 
to date, most of the data available on BHMT regulation come from early studies on the effects 
exerted in the whole methionine cycle by several hormonal treatments. Increases in BHMT activity 
and mRNA levels were observed by the action of hydrocortisone, cortisol and triamcinolone, 
whereas growth hormone only induced BHMT mRNA [18,34,65,70-76]. On the other hand, 
reductions in activity were described for thyroxine and renal hypertrophia induced by testosterone 
[18,34,65,70,71,75,78], in this last case methotrexate administration further reduced renal activity. 
Depletion of choline and betaine from liver produced by testosterone could be responsible for its 
effects, but the increased renal methionine uptake can also contribute. Insulin was effective in 
counteracting the stimulation of BHMT activity and mRNA levels produced by triamcinolone in rat 
hepatoma H4IIE cells [74]. These hormones affect the transcription rate in a manner parallel to their 
effects on mRNA levels, indicating their role in regulation of BHMT transcription. During 
pregnancy, tHcy also increases with inverse correlation to betaine after week 16. This effect could 
be due to the high levels of estrogens and cortisol that characterize this process [75]. Altogether, 
these results are in agreement with the presence of regulatory elements for some of these hormones 
in the BHMT promoter, but as pointed out earlier, deeper studies on their behavior are needed. 
7.3. Other agents. Administration of nitrous oxide to rats oxidized vitamin B12 and reduced 
MS activity in liver, leading to an increase in BHMT activity [79], a compensatory effect that was 
not observed in sheep [80]. Hypertonicity studies carried out in guinea pigs induced decreases in 
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BHMT mRNA and protein levels in liver and kidney [81], thus preserving betaine to protect against 
the osmotic stress in the organs involved in such regulatory system, while no effect was exerted on 
the high pancreatic activity. Other systems studied include valproate-induced neural tube defects 
[82] and microarray analysis of arsenic and TPA treated mouse livers [83].  
7.4. Knockout models. To date there is no knockout mouse for BHMT. However, there are 
several descriptions of knockout mice for other enzymes where BHMT function has been studied 
and that show the common feature of changes in tHcy levels. BHMT activity is increased in 
MTHFR (-/-) [84] and CT? (-/-) mice [85], whereas no change is observed in PEMT null mice [3] 
and CBS (+/-) [86]. Dietary betaine supplements induce BHMT activity, preventing severe hepatic 
steatosis in null MTHFR mice, while reducing Hcy levels around 40%. On the other hand, such a 
supplement in the drinking water reduces BHMT activity in CBS (+/-) mice and has no effect in 
PEMT (-/-). Such effects can be expected from the interrelationships between the eliminated 
activities and remethylation through BHMT (Figure 1). Thus, reduction in the flux through the 
folate cycle due to MTHFR elimination down-regulates MS, whereas partial suppression of CT? 
increases PC synthesis through transmethylation leading to a higher production of Hcy and an 
elevated consumption of SAM. Thus, increasing the use of betaine by BHMT will help in 
recovering methylation equivalents. Such a need disappears in PEMT (-/-) mice, and hence no 
effect on BHMT is observed, these results highlighting the importance of PEMT in Hcy production. 
In another model, the TNFR-1 KO mice, increased pHcy was also observed after intragastric 
ethanol infusion, and this elevation was reduced by betaine [87]. In this case, although a decrease in 
BHMT mRNA was detected no change in enzyme activity was observed.  
8. Interactions of BHMT.  
The extraordinary abundance of BHMT in liver, as well as its presence in the lens, where 
betaine is not produced, suggests its potential implication in processes other than methionine 
synthesis. To date, BHMT has been identified during the search for protein-protein interactions in 
several systems, although the significance of these observations remains unclear. These studies 
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include screening of cDNA expression and yeast two hybrid libraries, two-dimensional gel 
electrophoresis and immunoprecipitation. Among the interacting partners identified are apoB 
mRNA [54], tubulin [88], hepatitis B virus [HBV] [89], and transglutaminases [90]. In addition, 
BHMT2 and BHMT fragments were found in a prion protein [PrP] screening [2] and in 
autolysosomal and lysosomal membranes [91], respectively. The most promising results, providing 
a direct interaction, were those of tubulin, transglutaminase and lysosomal membranes. Fragments 
of BHMT were found in autolysosomal and lysosomal membranes [92], asssociation to 
microtubules was observed by colocalization using confocal microscopy, and coassembly of BHMT 
with tubulin dimers was also obtained [88]. In addition, transglutaminases modify BHMT on its C-
terminal end, or produce crosslinked 260 and 520 kDa multimers [90]. All these data suggest new 
roles for BHMT, since the fragments lacking part of the N-terminal may adopt different folding 
patterns, and hence could play another function. Such new foldings may also arise from association 
with tubulin or could derive from post-translational modifications. On the other hand, the rest of the 
studies mentioned failed to demonstrate a direct association to BHMTs. In fact, no direct binding of 
recombinant BHMT to apoB mRNA [93] or effects in its editing process [94] were observed, even 
when BHMT overexpression induces apoB mRNA, and both mRNAs are elevated in dietary 
treatments. Thus, as for apoB mRNA these data are suggestive of a role for BHMT in the process 
that could be indirect, not involving an interaction with these components. No immunoprecipitation 
of BHMT2 linked to PrP was reported [2], and its presence in membranes, in contrast to the 
cytosolic distribution of BHMT, was taken as indicative of the non-functional character of this 
interaction. However, this idea may have to be revised on the light of new data that found BHMT in 
hepatocyte membranes [33]. Immunoprecipitation also failed to prove interaction with HBV, but 
DIGE and mass spectrometry data from HBV hepatocellular carcinoma showed under expression of 
BHMT in well-differentiated tumours [95].  
9. Pathological implications of BHMT.  
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Changes in tHcy levels have been observed in important pathologies, but not always 
correlating to alterations in BHMT expression and activity levels. Moreover, when effects on this 
enzyme were detected they were not directly related to mutations in the protein sequence. In fact, 
the results suggest that BHMT alterations are a secondary event in the development of the 
pathologies studied, a role that may acquire more importance once some of the interactions 
mentioned above are studied in depth. Elevations of tHcy appear in cirrhosis [96], coronary artery 
disease [31] and renal disease [97], whereas decreases were observed in streptozotocin induced 
diabetes [72-74]. Decreased BHMT mRNA and protein levels were observed in cirrhotic patients 
and animal models, the strongest effect being observed upon HCV [98,99]. Implication of BHMT 
defects in renal disease is rather indirect and based on the presence of high plasma DMG levels and 
increased betaine excretion, thus suggesting that decreased enzyme activity is an important factor 
for the detected hyperhomocysteinemia. The changes observed in BHMT in diabetes depend 
strongly on the agent used for induction of this condition in the animal models, and hence while 
alloxan produces reductions in BHMT activity [100], streptozotocin-treated [72-74] and Zucker 
diabetic fatty rats show increased activity and mRNA levels [101]. Diabetes as well as alcoholism 
are known to increase losses of zinc, an effect that deserves further studies due to its putative 
consequences in BHMT structure and oxidation state.  
Hyperhomocysteinemia may appear as a consequence of defects in CBS or of inborn errors 
of remethylation due to either alterations in cobalamine metabolism and MS activity or in MTHFR 
function [102]. As mentioned before, elevated levels of tHcy are considered a risk factor for 
cardiovascular disease, and hence several studies have been devoted to find treatments to correct 
this problem. Folate fortification carried out in USA and Canada proved to reduce stroke-related 
mortality, and additional vitamin B6 and B12 supplements appeared to benefit certain subgroups 
among this population [103,104]. At present, treatment of patients with homocystinuria includes 
pyridoxine in combination with folic acid and vitamin B12 or methionine-restricted cystine-
supplemented diets, and recently, betaine has been included as an adjunctive to these treatments 
 17
[105,106]. However, betaine therapy, besides reducing tHcy, increases methionine levels and some 
cases of cerebral edema have been reported [102]. Benefits of betaine therapy result from increases 
in the flux through BHMT, although its activity has not been reported to be reduced in coronary 
artery disease [31]. Screening for BHMT mutations in vascular patients with 
hyperhomocysteinemia or subjected to coronary angiography identified 6 mutations [107,108]. 
Among them, G199S was found in conserved regions of the sequence, and a Chou/Fasman analysis 
suggests a turn to coil rearrangement for this mutant protein [107]. Another mutation, R239Q was 
also present in the ORF, but no significant association with the severity and extension of the disease 
was observed [108]. In fact, this human polymorphism is the normal allele in rat and mouse. The 
incidence of this mutation in neural tube defects has also been explored, leading to the conclusion 
that the Q allele may reduce the risk for development of this problem [109]. Linkage analysis of 
thoracic aortic aneurysm, familial abdominal aortic aneurysm, Wagner syndrome 
(vitreoretinopathy) and spinal muscular atrophy mapped to regions in chromosome 5 close to 
BHMT gene location, thus making it a putative candidate of study in these diseases [20,110]. The 
presence of BHMT in lens [29] could be related to its role in betaine removal when osmotic stress 
disappears, a key process since osmotic swelling is a major factor in the development of some types 
of cataracts [11,111]. Other studies of gene expression profiling have also shown upregulation of 
BHMT in Barret’s esophagous patients  [112].  
10. Future directions.  
The fact that BHMT is one of the most abundant proteins of mammalian liver, as well as its 
association to proteins such as tubulin suggest roles other than just remethylation of Hcy for this 
protein. At present no clues about these other functions exist, and the interactions reported deserve 
deeper studies. Its presence in the lens, an organ where the cells lack mitochondria, and hence 
choline oxidation, points also in that direction, as well as its identification bound to membranes. 
Protein moonlighting among metabolic enzymes is quite common, and hence it is a possibility that 
should not be excluded for BHMT. Another aspect that remains in doubt is the association state of 
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the protein. It is clear that recombinant BHMTs appear as tetramers, but data from purified proteins 
indicate higher oligomerization levels. Such discrepancies could be derived either from other 
oligomerization arrangements of the protein, as occurs in morpheeins, or from association with 
other proteins. In fact, interaction with transglutaminases produces higher order association 
arrangements. Little information exists regarding post-translational modifications or other levels of 
regulation. Finally, the role, structure, and regulation of BHMT2 are almost unknown. Altogether, 
the data available to date are centered on the traditional role of BHMT in methylation, but new 
possibilities are being opened that seem to link this enzyme to key processes that remain 
unexplored.  
 
11. References. 
1 Ueland P. M. and Refsum H. (1989) Plasma homocysteine, a risk factor for vascular disease: 
plasma levels in health, disease, and drug therapy. J. Lab. Clin. Med. 114, 473-501 
2 Chadwick L. H., McCandless S. E., Silverman G. L., Schwartz S., Westaway,D. and Nadeau J. H. 
(2000) Betaine-homocysteine methyltransferase-2: cDNA cloning, gene sequence, physical map-
ping, and expression of the human and mouse genes. Genomics 70, 66-73, and references therein 
3 Noga A. A., Stead L. M., Zhao Y., Brosnan M. E., Brosnan J. T. and Vance D. E. (2003) Plasma 
homocysteine is regulated by phospholipid methylation. J. Biol. Chem. 278, 5952-5955, and 
references therein 
4 Brosnan J. T., Jacobs R. L., Stead L. M. and Brosnan M. E. (2004) Methylation demand: a key 
determinant of homocysteine metabolism. Acta Biochim. Pol. 51, 405-413, and references therein 
5 Refsum H., Helland S. and Ueland P. M. (1989) Fasting plasma homocysteine as a sensitive 
parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate 
treatment. Clin. Pharmacol. Ther. 46, 510-520 
6 Mato J. M., Alvarez L., Ortiz P. and Pajares M. A. (1987) S-adenosylmethionine synthesis: 
molecular mechanisms and clinical implications. Pharmacol. Ther. 73, 265-280 
 19
7 Jacobs R. L., House J. D., Brosnan M. E. and Brosnan J. T. (1998) Effects of streptozotocin-
induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 47, 
1967-1970 
8 Garrow T. A. (1996) Purification, kinetic properties, and cDNA cloning of mammalian betaine-
homocysteine methyltransferase. J. Biol. Chem. 271, 22831-22838 
9  Finkelstein J. D. and Martin J.J. (1984) Methionine metabolism in mammals. Distribution of 
homocysteine between competing pathways. J. Biol. Chem. 259, 9508-9513  
10 Craig S. A. (2004) Betaine in human nutrition. Am. J. Clin. Nutr. 80, 539-546 
11  García-Pérez A. and Burg M. B. (1991) Renal medullary organic osmolytes. Physiol. Rev. 71, 
1081-1115  
12 Zeisel S. H., Story D. L., Wurtman R. J. and Brunengraber, H. (1980) Uptake of free choline by 
isolated perfused rat liver. Proc. Natl. Acad. Sci. 77, 4417-4419 
13 Porter R. K., Scott J. M. and Brand M. D. (1993) Characterization of betaine efflux from rat liver 
mitochondria. Biochim. Biophys. Acta 1141, 269-274, and references therein 
14 Kennedy E. G. and Weiss S. B. (1956) The function of cytidine coenzymes in the biosynthesis of 
phospholipids. J. Biol. Chem. 222, 193-214 
15 Bremer J. and Greenberg D. M. (1959) Mono and dimethylethanolamine isolated from rat liver 
phospholipids. Biochim. Biophys. Acta 37, 173-175 
16 Sundler R. and Akesson B. (1975) Regulation of phospholipid biosynthesis in isolated rat 
hepatocytes. J. Biol. Chem. 250, 3359-3367 
17 Porter R. K., Scott J. M. and Brand M. D. (1992) Choline transport into rat liver mitochondria. 
Characterization and kinetics of a specific transporter. J. Biol. Chem. 26, 14637-14646 
18 Park E. I. and Garrow T. A. (1999) Interaction between dietary methionine and methyl donor 
intake on rat liver betaine-homocysteine methyltransferase gene expression and organization of the 
human gene. J. Biol. Chem. 274, 7816-7824, and references therein 
 20
19 Neece D. J., Griffiths M. A. and Garrow T. A. (2000) Isolation and characterization of a mouse 
betaine-homocysteine S-methyltransferase gene and pseudogene. Gene 250, 31-40 
20 Sunden S. L., Renduchintala M. S., Park E. I., Miklasz S. D. and Garrow T. A. (1997) Betaine-
homocysteine methyltransferase expression in porcine and human tissues and chromosomal 
localization of the human gene. Arch. Biochem. Biophys. 345, 171-174 
21 Castro C., Breksa A. P. III, Salisbury, E.M. and Garrow T.A. (2001) Betaine-homocysteine S-
methyltransferase (BHMT) transcription is inhibited by S-adenosylmethionine (AdoMet). In: 
Chemistry and Biology of Pteridines and Folates. pp. 549-556, Milstien S., Kapatos G., Levine R. 
A. and Shane B. (eds.), Kluwer, Norwell MA 
22 McKeever M. P., Weir D. G., Molloy A. and Scott J. M. (1991) Betaine-homocysteine 
methyltransferase: organ distribution in man, pig and rat and subcellular distribution in the rat. Clin. 
Sci. 81, 551-556 
23 Balinska M. and Paszewski A. (1979) Betaine-homocysteine methyltransferase in the fungus 
Aspergillus nidulans. Biochem. Biophys. Res. Commun. 91, 1095-1100 
24 Waditee R. and Incharoensakdi A. (2001) Purification and kinetic properties of betaine-
homocysteine methyltransferase from Aphanothece halophytica. Curr. Microbiol. 43, 107-111 
25 Fisher M. C., Zeisel S. H., Mar M. H. and Sadler T. W. (2002) Perturbations in choline 
metabolism cause neural tube defects in mouse embryos in vitro. FASEB J. 16, 619-621 
26 Yamashita T., Hashimoto S., Kaneko S., Nagai S., Toyoda N., Suzuki T., Kobayashi K. and 
Matsushima K. (2000) Comprehesive gene expression profile of a normal human liver. Biochem. 
Biophys. Res. Commun. 269, 110-116  
27 Martin J.J. and Finkelstein J. D. (1981) Enzymatic determination of betaine in rat tissues. Anal. 
Biochem. 111, 72-76 
28 Xue G. P. and Snoswell A. M. (1986) Developmental changes in the activities of enzymes 
related to methyl group metabolism in sheep tissues. Comp. Biochem. Physiol. 83B, 115-120 
 21
29 Rao P. V., Garrow T. A., John F., Garland D., Millian N. S. and Zigler J. S. Jr. (1998) Betaine-
homocysteine methyltransferase is a developmentally regulated enzyme crystallin in rhesus monkey 
lens. J. Biol. Chem. 273, 30669-30674 
30 Skiba W. E., Taylor M. P., Wells M. S., Mangum J. H. and Awad W. M. Jr. (1982) Human 
hepatic methionine biosynthesis. Purification and characterization of betaine:homocysteine S-
methyltransferase. J. Biol. Chem.  257, 14944-14948 
31 Dudman N. P., Wilcken D. E., Wang, J., Lynch J. F., Macey D. and Lundberg P. (1993) 
Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, 
cofactor therapy, and enzymology. Arterioscler. Thromb. 13, 1253-1260 
32 Delgado-Reyes C. V., Wallig M. A. and Garrow T. A. (2001) Immunohistochemical detection of 
betaine-homocysteine S-methyltransferase in human, pig, and rat liver and kidney. Arch. Biochem. 
Biophys. 393, 184-186 
33 Sehayek E., Wang R., Ono J. G., Zinchuk V. S., Duncan E. M., Shefer S., Vance D. E., 
Ananthanarayanan M., Chait B.T. and Breslow J. L. (2003) Localization of the PE methylation 
pathway and SR-BI to the canalicular membrane: evidence for apical PC biosynthesis that may 
promote biliary excretion of phospholipid and cholesterol. J. Lipid Res. 44, 1605-1613 
34 Finkelstein J. D., Harris B. J. and Kyle W. E. (1972) Methionine metabolism in mammals: 
kinetic study of betaine-homocysteine methyltransferase. Arch. Biochem. Biophys. 153, 320-324 
35 Lee K. H., Cava M., Amiri P., Ottoboni T. and Lindquist R. N. (1992) Betaine: homocysteine 
methyltransferase from rat liver: purification and inhibition by a boronic acid substrate analog. 
Arch. Biochem. Biophys. 292, 77-86 
36 Bose N. and Momany C. (2001) Crystallization and preliminary X-ray crystallographic studies 
of recombinant human betaine-homocysteine S-methyltransferase. Acta Crystallogr. D Biol. 
Crystallogr. 57, 431-433 
 22
37 González B., Pajares M. A., Too H. P., Garrido F., Blundell T. L. and Sanz-Aparicio, J. (2002) 
Crystallization and preliminary X-ray study of recombinant betaine-homocysteine S-
methyltransferase from rat liver. Acta Crystallogr. D Biol. Crystallogr. 58, 1507-1510 
38 Evans J. C., Huddler D. P., Jiracek J., Castro C., Millian N. S., Garrow T. A. and Ludwig M. L. 
(2002) Betaine-homocysteine methyltransferase: zinc in a distorted barrel. Structure 10, 1159-1171 
39 Castro C., Gratson A. A., Evans J. C., Jiracek J., Collinsova M., Ludwig M. L. and Garrow T. A. 
(2004) Dissecting the catalytic mechanism of betaine-homocysteine S-methyltransferase by use of 
intrinsic tryptophan fluorescence and site-directed mutagenesis. Biochemistry 43, 5341-5351 
40 Millian N. S. and Garrow T. A. (1998) Human betaine-homocysteine methyltransferase is a zinc 
metalloenzyme. Arch. Biochem. Biophys. 356, 93-98 
41 González B., Campillo N., Garrido F., Gasset M., Sanz-Aparicio J. and Pajares M. A. (2003) 
Active-site mutagenesis study of rat liver betaine-homocysteine S-methyltransferase. Biochem. J. 
370, 945-952 
42 Finkelstein J. D., Kyle W. E. and Harris B. J. (1974) Methionine metabolism in mammals: 
regulatory effects of S-adenosylhomocysteine. Arch. Biochem. Biophys. 165, 774-779 
43 Awad W. M. Jr, Whitney P. L., Skiba W. E., Mangum J. H. and Wells M. S. (1983) Evidence for 
direct methyl transfer in betaine: homocysteine methyltransferase. J. Biol. Chem. 258, 12790-12792 
44 Finkelstein J. D. and Martin J. J. (1984) Inactivation of betaine-homocysteine methyltransferase 
by adenosylmethionine and adenosylethionine. Biochem. Biophys. Res. Commun. 118, 14-19 
45 Collinsova M., Castro C., Garrow T. A., Yiotakis A., Dive V. and Jiracek J. (2003) Combining 
combinatorial chemistry and affinity chromatography: highly selective inhibitors of human betaine: 
homocysteine S-methyltransferase. Chem. Biol. 10, 113-122 
46 Allen R. H., Stabler S. P. and Lindenbaum J. (1993) Serum betaine, N,N-dimethylglycine and N-
methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of 
metabolism. Metabolism 42, 1448-1460 
 23
47 Jiracek J., Collinsova M., Rosenberg I., Budesinsky M., Protivinska E., Netusilova H. and 
Garrow T.A. (2006) S-alkylated homocysteine derivatives: New inhibitors of human betaine-
homocysteine S-methyltransferase. J. Med. Chem. 49, 3982-3989 
48 Breksa A. P. 3rd and Garrow T. A. (1999) Recombinant human liver betaine-homocysteine S-
methyltransferase: identification of three cysteine residues critical for zinc binding. Biochemistry 
38, 13991-13998 
49 González B., Pajares M. A., Martínez-Ripoll M., Blundell T. L. and Sanz-Aparicio J. (2004) 
Crystal structure of rat liver betaine homocysteine s-methyltransferase reveals new oligomerization 
features and conformational changes upon substrate binding. J. Mol. Biol. 338, 771-782 
50 Breksa A. P. 3rd and Garrow T. A. (2002) Random mutagenesis of the zinc-binding motif of 
betaine-homocysteine methyltransferase reveals that Gly 214 is essential. Arch. Biochem. Biophys. 
399, 73-80 
51 Miller C. M., Szegedi S. S. and Garrow T. A. (2005) Conformation-dependent inactivation of 
human betaine-homocysteine S-methyltransferase by hydrogen peroxide in vitro. Biochem. J. 392, 
443-448 
52 Szegedi S. S. and Garrow T. A. (2004) Oligomerization is required for betaine-homocysteine S-
methyltransferase function. Arch. Biochem. Biophys. 426, 32-42 
53 Garrido F., Gasset M., Sanz-Aparicio J., Alfons, C. and Pajares M. A. (2005) Rat liver betaine-
homocysteine S-methyltransferase equilibrium unfolding: insights into intermediate structure 
through tryptophan substitutions. Biochem. J. 391, 589-599 
54 Sowden M. P., Collins H. L., Smith H. C., Garrow T. A., Sparks J. D. and Sparks C. E. (1999) 
Apolipoprotein B mRNA and lipoprotein secretion are increased in McArdle RH-7777 cells by 
expression of betaine-homocysteine S-methyltransferase. Biochem. J. 341, 639-645 
55 Doi T., Kawata T., Tadano N., Iijima T. and Maekawa A. (1989) Effect of vitamin B12-deficien-
cy on the activity of hepatic cystathionine beta-synthase in rats. J. Nutr. Sci. Vitaminol. 35, 101-110 
 24
56 Finkelstein J. D., Martin J. J., Harris B. J. and Kyle W. E. (1983) Regulation of hepatic betaine-
homocysteine methyltransferase by dietary betaine. J. Nutr. 113, 519-521 
57 Finkelstein J. D. and Martin J. J. (1986) Methionine metabolism in mammals. Adaptation to 
methionine excess. J. Biol. Chem. 261, 1582-1587 
58 Finkelstein J. D., Martin J. J. and Harris B. J. (1986) Effect of dietary cystine on methionine 
metabolism in rat liver. J. Nutr. 116, 985-990 
59 Finkelstein J. D., Martin J. J. and Harris B. J. (1988) Methionine metabolism in mammals. The 
methionine-sparing effect of cystine. J. Biol. Chem. 263, 11750-11754 
60 Uthus E. O., Yokoi K. and Davis C. D. (2002) Selenium deficiency in Fisher-344 rats decreases 
plasma and tissue homocysteine concentrations and alters plasma homocysteine and cysteine redox 
status. J. Nutr. 132, 1122-1128 
61 Davis C. D. and Uthus E. O. (2003) Dietary folate and selenium affect dimethylhydrazine-
induced aberrant crypt formation, global DNA methylation and one-carbon metabolism in rats. J. 
Nutr. 133, 2907-2914 
62 Radcliffe B. C. and Egan A. R. (1978) The effect of diet and of methionine loading on activity of 
enzymes in the transulfuration pathway in sheep. Aust. J. Biol. Sci. 31, 105-114 
63 Emmert J. L., Webel D. M., Biehl R. R., Griffiths M. A., Garrow L. S., Garrow T. A. and Baker 
D. H. (1998) Hepatic and renal betaine-homocysteine methyltransferase activity in pigs as affected 
by dietary intakes of sulfur amino acids, choline, and betaine. J. Anim. Sci. 76, 606-610 
64 Halsted C. H., Griggs R. C. and Harris J. W. (1967) The effect of alcoholism on absorption of 
folic acid (H3-PGA) evaluated by plasma levels and urine excretion. J. Lab. Clin. Med. 69, 116-131 
65 Finkelstein J. D., Cello J. P. and Kyle W. E. (1974) Ethanol-induced changes in methionine 
metabolism in rat liver. Biochem. Biophys. Res. Commun. 61, 525-531, and references therein 
66 Barak A. J., Beckenhauer H. C. and Tuma D. J. (1996) Betaine effects on hepatic methionine 
metabolism elicited by short-term ethanol feeding. Alcohol 13, 483-486 
 25
67 Barak A. J., Beckenhauer H. C., Junnila M. and Tuma D. J. (1993) Dietary betaine promotes 
generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty 
infiltration. Alcohol. Clin. Exp. Res. 17, 552-555 
68 Halsted C. H., Villanueva J. A., Devlin A. M., Niemela O., Parkkila S., Garrow T. A., Wallock 
L. M., Shigenaga M. K., Melnyk S. And James S. J. (2002) Folate deficiency disturbs hepatic 
methionine metabolism and promotes liver injury in the ethanol-fed micropig. Proc. Natl. Acad. 
Sci. 99, 10072-10077 
69 Barak A. J., Beckenhauer H. C. and Tuma D. J. (1991) Hepatic transmethylation and blood 
alcohol levels. Alcohol Alcohol. 26, 125-128 
70 Finkelstein J. D., Kyle W. and Harris B. J. (1971) Methionine metabolism in mammals. 
Regulation of homocysteine methyltransferases in rat tissue. Arch. Biochem. Biophys. 146, 84-92 
71 Finkelstein J. D., Kyle W. E. and Harris B. J. (1974) Methionine metabolism in mammals: 
regulatory effects of S-adenosylhomocysteine. Arch. Biochem. Biophys. 165, 774-779 
72 Jacobs R. L., House J. D., Brosnan M. E. and Brosnan J. T. (1998) Effects of streptozotocin-
induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Diabetes 47, 
1967-1970 
73 Nieman K. M., Rowling M. J., Garrow T. A. and Schalinske K. L. (2004) Modulation of methyl 
group metabolism by streptozotocin-induced diabetes and all-trans-retinoic acid. J. Biol. Chem. 
279, 45708-45712 
74 Ratnam S., Wijekoon E. P., Hall B., Garrow T. A., Brosnan M. E. and Brosnan J. T. (2006) 
Effects of diabetes and insulin on betaine-homocysteine S-methyltransferase expression in rat liver. 
Am. J. Physiol. Endocrinol. Metab. 290, E933-E939 
75 Velzing-Aarts F. V., Holm P. I., Fokkema M. R., van der Dijs F. P., Ueland P. M. and Muskiet 
F. A. (2005) Plasma choline and betaine and their relation to plasma homocysteine in normal 
pregnancy. Am. J. Clin. Nutr. 81, 1383-1389 
 26
76 Uthus E. O. and Brown-Borg H.M. (2006) Methionine flux to transsulfuration is enhanced in the 
long living Ames dwarf mouse. Mech. Ageing Dev. 127, 444-450 
77 Tanghe K. A., Garrow T. A. and Schalinske K. L. (2004) Triiodothyronine treatment attenuates 
the induction of hepatic glycine N-methyltransferase by retinoic acid and elevates plasma 
homocysteine concentrations in rats. J. Nutr. 134, 2913-2918 
78 Chmurzynska W., Manteuffel-Cymborowska M., Szlazak M. and Grzelakowska-Sztabert B. 
(1993) MTX does not affect enhanced biosynthesis and metabolism of S-adenosylmethionine in 
testosterone-induced hypertrophic mouse kidney. Adv. Exp. Med. Biol. 338, 699-702 
79 Lumb M., Sharer N., Deacon R., Jennings P., Purkiss P., Perry J. and Chanarin I. (1983) Effects 
of nitrous oxide-induced inactivation of cobalamin on methionine and S-adenosylmethionine 
metabolism in the rat. Biochim. Biophys. Acta 756, 354-359 
80 Xue G. P., Snoswell A. M. and Runciman W. B. (1986) Perturbation of methionine metabolism 
in sheep with nitrous-oxide-induced inactivation of cobalamin. Biochem. Int. 12, 61-69 
81 Delgado-Reyes C. V. and Garrow T. A. (2005) High sodium chloride intake decreases betaine-
homocysteine S-methyltransferase expression in guinea pig liver and kidney. Am. J. Physiol. Regul. 
Integr. Comp. Physiol. 228, R182-R187 
82 Ubeda N., Alonso-Aperte E. and Varela-Moreiras G. (2002) Acute valproate administration 
impairs methionine metabolism in rats. J. Nutr. 132, 2737-2742 
83 Liu J., Xie Y., Merrick B. A., Shen J., Ducharme D. M., Collins J., Diwan B. A., Logsdon D. 
and Waalkes M. P.  (2006) Transplacental arsenic plus postnatal 12-O-teradecanoyl phorbol-13-
acetate exposures associated with hepatocarcinogenesis induce similar aberrant gene expression 
patterns in male and female mouse liver. Toxicol Appl Pharmacol. 213, 216-223  
84 Schwahn B. C., Chen Z., Laryea M. D., Wendel U., Lussier-Cacan S., Genest J. Jr, Mar M. H., 
Zeisel S. H., Castro C., Garrow T. and Rozen R. (2003) Homocysteine-betaine interactions in a 
murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB J. 17, 512-514 
 27
85 Jacobs R. L., Stead L. M., Devlin C., Tabas I., Brosnan M. E., Brosnan J. T. and Vance D. E. 
(2005) Physiological regulation of phospholipid methylation alters plasma homocysteine in mice. J. 
Biol. Chem. 280, 28299-28305 
86 Schwahn B. C., Wendel U., Lussier-Cacan S., Mar M. H., Zeisel S. H., Leclerc D., Castro C., 
Garrow T. and Rozen R. (2004) Effects of betaine in a murine model of mild cystathionine-beta-
synthase deficiency. Metabolism 53, 594-599 
87 Ji C., Deng Q. and Kaplowitz N. (2004) Role of TNF-alpha in ethanol-induced 
hyperhomocysteinemia and murine alcoholic liver injury. Hepatology 40, 442-451 
88 Sandu C., Nick P., Hess D., Schiltz E., Garrow T. A. and Brandsch R. (2000) Association of 
betaine-homocysteine S-methyltransferase with microtubules. Biol. Chem. 381, 619-622 
89 Bai G. Q., Cheng J., Zhang S. L., Huang Y. P., Wang L., Liu Y. and Lin S. M. (2005) Screening 
of hepatocyte proteins binding to complete S protein of hepatitis B virus by yeast-two hybrid 
system. World J. Gastroenterol. 11, 3899-3904 
90 Ichikawa A., Ohashi Y., Terada S., Natsuka S. and Ikura K. (2004) In vitro modification of 
betaine-homocysteine S-methyltransferase by tissue-type transglutaminase. Int. J. Biochem. Cell. 
Biol. 36, 1981-1992 
91 Ueno T., Ishidoh K., Mineki R., Tanida I., Murayama K., Kadowaki M. and Kominami E. 
(1999) Autolyso-somal membrane-associated betaine homocysteine methyltransferase. Limited 
degradation fragment of a sequestered cytosolic enzyme monitoring autophagy. J. Biol. Chem. 274, 
15222-15229 
92 Furuya N., Kanazawa T., Fujimura S., Ueno T., Kominami E. and Kadowaki M. (2001) 
Leupeptin-induced appearance of partial fragment of betaine homocysteine methyltransferase 
during autophagic maturation in rat hepatocytes. J. Biochem. 129:,313-320 
93 Collins H. L., Sparks C. E. and Sparks J. D. (2000) B48 preferentially translated over B100 in 
cells with increased endogenous apoB mRNA. Biochem. Biophys. Res. Commun. 273, 1156-1160 
 28
94 Sparks J. D., Collins H. L., Chirieac D. V., Cianci J., Jokinen J., Sowden M. P., Galloway C. A. 
and Sparks C. E. (2006) Hepatic very-low-density lipoprotein and apolipoprotein B production are 
increased following in vivo induction of betaine-homocysteine S-methyltransferase. Biochem J. 
395, 363-371 
95 Liang C. R., Leow C. K., Neo J. C., Tan G. S., Lo S. L., Lim J. W., Seow T. K., Lai P. B. and 
Cheng M. C. (2005) Proteome analysis of human hepatocellular carcinoma tissues by two-
dimensional difference gel electrophoresis and mass spectrometry. Proteomics 5, 2258-2271 
96  Look M. P., Riezler R., Reichel C., Brensing K. A., Rockstroh J. K., Stabler S.P, Spengler U., 
Berthold H. K. and Sauerbruch T. (2000) Is the increase in serum cystathionine levels in patients 
with liver cirrhosis a consequence of impaired homocysteine transsulfuration at the level of gamma-
cystathionase? Scand. J. Gastroenterol. 35, 866-872 
97 McGregor D. O., Dellow W. J., Lever M., George P. M., Robson R. A. and Chambers S. T. 
(2001) Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine 
concentrations. Kidney Int. 59, 2267-2272 
98 Avila M. A., Berasain C., Torres L., Martin-Duce, A., Corrales F. J., Yang H., Prieto J., Lu S. 
C., Caballería J., Rodes J. and Mato J.M. (2000) Reduced mRNA abundance of the main enzymes 
involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J. 
Hepatol. 33, 907-914 
99 Forestier M., Banninger R., Reichen J. and Solioz M. (2003) Betaine homocysteine 
methyltransferase: gene cloning and expression analysis in rat liver cirrhosis. Biochim. Biophys. 
Acta 1638, 29-34 
100 Xue G. P. and Snoswell A. M. (1985) Disturbance of methyl group metabolism in alloxan-
diabetic sheep. Biochem. Int. 10, 897-905 
101 Wijekoon E. P., Hall B., Ratnam S., Brosnan M. E., Zeisel S. H. and Brosnan J. T. (2005) 
Homocysteine metabolism in ZDF (type 2) diabetic rats. Diabetes 54, 3245-3251 
 29
102 Lawson-Yuen A. and Levy H. L. (2006) The use of betaine in the treatment of elevated 
homocysteine. Mol. Genet. Metab. PMID: 16545978 
103 Yang Q., Botto L. D., Ericsson J. D., Berry R. J., Sambell C., Johansen H. and Friedman J. M. 
(2006) Circulation 113, 1335-1343 
104 Spence J. D., Bang H., Chambless L. E. and Stampfer M. J. (2005) Vitamin intervention for 
stroke prevention trial. Stroke 36, 2404-2409  
105 Singh R. H., Kruger W. D., Wang L., Pasquali M. and Elsas L. J. 2
nd
 (2004) Cystathionine 
beta-synthase deficiency: effects of betaine supplementation after methionine restriction in B6-
nonresponsive homocystinuria. Genet. Med. 6, 90-95 
106 Yap S. (2003) Classical homocystinuria: Vascular risk and its prevention. J. Inherit. Metab. 
Dis. 26, 259-265. 
107 Heil S. G., Lievers K. J., Boers G. H., Verhoef P., den Heijer M., Trijbels F. J. and Blom H. J. 
(2000) Betaine-homocysteine methyltransferase (BHMT): genomic sequencing and relevance to 
hyperhomocysteinemia and vascular disease in humans. Mol. Genet. Metab. 71, 511-519 
108 Weisberg I. S., Park E., Ballman K. V., Berger P., Nunn M., Suh D. S., Breaksa A. P. 3rd, 
Garrow T. A. and Rozen R. (2003) Investigations of a common genetic variant in betaine-
homocysteine methyltransferase (BHMT) in coronary artery disease. Atherosclerosis 167, 205-214 
109 Morin I., Platt R., Weisberg I., Sabbaghian N., Wu Q., Garrow, T. A., Rozen R. (2003) 
Common variant in betaine-homocysteine methyltransferase (BHMT) and risk for spina bifida. Am. 
J. Med. Genetics 119A, 172-176 
110 van Vlijmen-van Keulen C. J., Vahl A. C., Hennekam R. C., Rauwerda J. A. and Pals G. (2003) 
Genetic linkage of candidate genes in families with abdominal aortic aneurysms? Eur. J. Vasc. 
Endovasc. Surg. 26, 205-210 
111 Kinoshita J. H. (1974) Mechanisms initiating cataract formation. Invest. Ophthalmol. 13, 713-
724 
 30
112 Cheng P., Gong J., Wang T., Chen J., Liu G. S. and Zhang R. (2005) Gene expression in rats 
with Barrett's esophagus and esophageal adenocarcinoma induced by gastroduodenoesophageal 
reflux. World J. Gastroenterol. 11, 5117-5122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 31
Figure legends. 
Figure 1. Homocysteine metabolism in the liver. The figure shows the reactions involved in Hcy 
metabolism in the liver. Enzymes are shown in orange, cofactors in green, cell metabolites in light 
blue, and plasma metabolites in pink. Abbreviations correspond to: Hcy, homocysteine; MTHF, 
methyl tetrahydrofolate; THF tetrahydrofolate; SAM, S-adenosylmethionine; SAH, S-
adenosylhomocysteine; PE, phosphatidylethanolamine; PC, phosphatidylcholine; DMG, 
dimethylglycine; MS, methionine synthase (EC 2.1.1.13); BHMT, betaine homocysteine 
methyltransferase (EC 2.1.1.5); MAT, methionine adenosyltransferase (EC 2.5.1.6); SAHH, S-
adenosylhomocysteine hydrolase (EC 3.3.1.1); PEMT, phosphatidylethanolamine N-
methyltransferase (EC 2.1.1.17); PLD, phospholipase D (EC 3.1.4.4); ChoOX, choline oxidase (EC 
1.1.3.17); BADH, betaine aldehyde dehydrogenase (EC 1.2.1.8); CBS, cysthathionine ? synthase 
(EC 4.2.1.22); C?L, cystathionine ?-lyase or cystathionase (EC 4.4.1.1).  
 
Figure 2. Betaine homocysteine methyltransferase structure.  (A) A schematic representation of 
the structure of rat BHMT tetramer, with one of the monomers highlighted in magenta. (B) The 
details of the monomer are depicted. Secondary structure elements involved in folding are shown in 
colors: helix ?4 of the barrel (green); helix ?7 of the barrel (yellow); dimerization arm around 
W331 (blue); and C-terminal loop around W373 (magenta).  
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Table 1 
 Inhibitors of BHMT. The compounds exerting the strongest effects on BHMT activity are 
shown, along with their IC50 and the source of the protein used in the assay. 
 
Inhibitor IC50 Type of inhibition BHMT 
source 
Ref. 
L-methionine  
2 mM 
Competitive against betaine 
Noncompetitive against L-Hcy 
Rat 
human 
34, 46 
DMG  
10 µM 
noncompetitive Rat human 30, 
34, 46 
D- and L- cistine   rat 34 
SAM   Rat human 44, 46 
SAH  Competitive against L-Hcy 
Noncompetititve against betaine 
rat 42 
3,3-dimethylbutirate 450 µM Competitive against betaine Human 30 
isovalerate 300 µM Competitive against betaine human 30 
butirate 1 mM Competitive against betaine human 30 
CB-Hcy 6.5 x 10-6M Competitive against betaine human 30, 43 
TAMB 45 µM Competitive against betaine rat 35 
Val-Phe-?[PO2—-CH2]-Leu-His-NH2 1 µM  rat 45 
(R,S)-5-(3-amino-3-carboxy-
propylsulfanyl)-pentanoic acid 
87 nM Competitive against betaine Human 
recombinant 
47 
(R,S)-6-(3-amino-3-carboxy-
propylsulfanyl)-hexanoic acid 
200 nM  Human 
recombinant 
47 
(R,S)-2-amino-4-(2-
carboxymethylsulfanyl-
ethylsulfanyl)-butyric acid 
96 nM  Human 
recombinant 
47 
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